Size of thermosensitive liposomes influences content release

Hossann, Martin; Wang, Tungte; Wiggenhorn, Michael; Schmidt, Rebecca; Zengerle, Anja; Winter, Gerhard; Eibl, Hansjörg; Peller, Michael; Reiser, Maximilian; Issels, Rolf D.; Lindner, Lars H.

doi:10.1016/j.jconrel.2010.08.013

Cited by 99 publications

(79 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lipid-grafted PEG (eg, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy(PEG)-2000, DSPE-PEG 2000 , Figure 5A) is commonly used in liposomes to create a steric barrier for inhibition of uptake by the reticuloendothelial system and increased blood circulation time, [47][48][49] but also potentially affects vesicle stability ( Figure 5B). 50 In addition to phospholipid composition, the manifestation of heat-triggered drug release depends to some degree on the drug molecule encapsulated ( Figure 4C), 28,51,52 vesicle size, 51 and the presence of serum components. 45,52 In vitro and in vivo behavior of selected formulations Until now distinct liposomal formulations have been described, which will be discussed in detail in this section (Table 1).…”

Section: Influence Of Lipid Composition On Drug Releasementioning

confidence: 99%

“…84,86,91,92 This makes it possible to strongly change an MRI signal by altering temperature. 92 The maximum achievable signal change depends on the type of contrast agent, 86 lipid composition, 86,91 vesicle size, 51,91 and concentration of the encapsulated contrast agent. 86,91 The heating method might also play a role, eg, focused ultrasound adds a mechanical release component to the signal mechanism.…”

Section: Signal Mechanismmentioning

confidence: 99%

“…52 Moreover, the stability of DPPG 2 -TSL was less affected by size changes in the range of 100-150 nm compared to surfactant containing LTSL. 51 Incorporation of 10% mol hexadecylphosphocholine (HePC; Figure 5A) into the membrane of DPPG 2 -TSL further increased the release rate of the encapsulated drug, similar to lyso-PC. 71 HePC is structurally related to lyso-PC, but has better chemical and metabolic stability, and is approved as a lipophilic drug for the treatment of skin metastasis in breast cancer and for leishmaniasis.…”

mentioning

confidence: 96%

See 2 more Smart Citations

Thermosensitive liposomal drug delivery systems: state of the art review

Kneidl¹,

Peller²,

Winter³

et al. 2014

IJN

Self Cite

146

View full text Add to dashboard Cite

Thermosensitive liposomes are a promising tool for external targeting of drugs to solid tumors when used in combination with local hyperthermia or high intensity focused ultrasound. In vivo results have demonstrated strong evidence that external targeting is superior over passive targeting achieved by highly stable long-circulating drug formulations like PEGylated liposomal doxorubicin. Up to March 2014, the Web of Science listed 371 original papers in this field, with 45 in 2013 alone. Several formulations have been developed since 1978, with lysolipid-containing, low temperature-sensitive liposomes currently under clinical investigation. This review summarizes the historical development and effects of particular phospholipids and surfactants on the biophysical properties and in vivo efficacy of thermosensitive liposome formulations. Further, treatment strategies for solid tumors are discussed. Here we focus on temperature-triggered intravascular and interstitial drug release. Drug delivery guided by magnetic resonance imaging further adds the possibility of performing online monitoring of a heating focus to calculate locally released drug concentrations and to externally control drug release by steering the heating volume and power. The combination of external targeting with thermosensitive liposomes and magnetic resonance-guided drug delivery will be the unique characteristic of this nanotechnology approach in medicine.

show abstract

Section: Influence Of Lipid Composition On Drug Releasementioning

confidence: 99%

Section: Signal Mechanismmentioning

confidence: 99%

mentioning

confidence: 96%

See 1 more Smart Citation

Thermosensitive liposomal drug delivery systems: state of the art review

Kneidl¹,

Peller²,

Winter³

et al. 2014

IJN

Self Cite

146

View full text Add to dashboard Cite

show abstract

“…27,71,72 The new generation of doxorubicin-loaded liposomes are thermosensitive liposomes (TSLs), which release their encapsulated drugs in regions where local tissue temperatures are elevated. 76 Compared with non-TSLs that remain stable and do not release drug in the physiologic temperature range, TSLs undergo a gel-to-liquid crystalline phase change when heated that renders the liposomes more permeable, releasing their encapsulated drugs. ThermoDox ® (Celsion Corporation, Lawrenceville, NJ), a proprietary TSL encapsulation of doxorubicin, has recently begun Phase III clinical trials for the treatment of hepatocellular carcinoma.…”

Section: Clinical Studies Of Liposomal-based Anticancer Drugs: Doxorumentioning

confidence: 99%

Clinical development of liposome based drugs: formulation, characterization, and therapeutic efficacy

Chang

Yeh²

2011

IJN

333

159

View full text Add to dashboard Cite

Abstract:Research on liposome formulations has progressed from that on conventional vesicles to new generation liposomes, such as cationic liposomes, temperature sensitive liposomes, and virosomes, by modulating the formulation techniques and lipid composition. Many research papers focus on the correlation of blood circulation time and drug accumulation in target tissues with physicochemical properties of liposomal formulations, including particle size, membrane lamellarity, surface charge, permeability, encapsulation volume, shelf time, and release rate. This review is mainly to compare the therapeutic effect of current clinically approved liposomebased drugs with free drugs, and to also determine the clinical effect via liposomal variations in lipid composition. Furthermore, the major preclinical and clinical data related to the principal liposomal formulations are also summarized.

show abstract

“…Although toxicity remains one of the chief complaints, liposomes are definitely one of the most successful non-viral vectors around. Already, several sustained-release liposomal drug formulations have been approved for human use and thermosensitive liposomes are being evaluated in clinical trials (Hossann et al, 2010). Lipids also dominate in gene therapy trials aimed at using non-viral vectors to treat cystic fibrosis (Griesenbach & Alton, 2009).…”

Section: Non-viral Vectorsmentioning

confidence: 99%